Business
Hemostemix Announces Peter Lacey as Chairman of the Board of Directors
Calgary, Alberta--(Newsfile Corp. - March 19, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF)...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Peter Lacey as Chairman of the Board of DirectorsCalgary, Alberta--(Newsfile Corp. - March 19, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce the election of Mr. Peter Lacey, ICD.D as Chairman of its Board of Directors. Peter Lacey is currently the Chairman of Cervus Equipment Corporation (CERV.TO), a company he and his partners started in 1999 and built from five John Deere dealerships into a company that owns 63 dealerships selling six brands in three countries with revenues of $1.1 Billion, paying a quarterly dividend of $0.11 per share. Mr. Lacey has been Chairman of Cervus Equipment since inception, and was President and Chief Executive Officer of Cervus Equipment Corporation and its predecessor entities from 1982 to April 2012. Mr. Lacey is a graduate of the Institute of Corporate Directors Education Program at the University of Toronto. \"Nominating Peter to the board of directors and electing him as its Chairman is a significant milestone for the Company, said Thomas Smeenk, President. \"Our team greatly appreciates Peter's business acumen, global company build-experience and leadership reputation for ethical business dealings, trust, transparency, and straightforwardness. I look forward to working with him, together with the board of directors, to incorporate the board's strategic guidance into our commercialization and growth execution plan,\" Smeenk said. \"As a significant, long term investor in Hemostemix, I am pleased to be asked to join the Board and be elected as its Chairman. Hemostemix and its patented technology offer significant potential to help thousands of patients globally with various conditions of ischemia and reducing potential loss of limbs. Successful execution of commercializing this technology to bring significant shareholder value will be our prime objective,\" said Mr. Lacey.ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, plac...